Curanex shares surge 45.77% intraday after completing GMP pilot batch for Phyto-N, advancing 2026 IND filing.

Curanex (CURX) surged 45.77% intraday following the completion of a GMP-compliant pilot batch for Phyto-N, a critical step toward its 2026 IND filing for ulcerative colitis. The rally was driven by both regulatory progress—marking a key milestone in the drug’s development—and technical factors, including a breakout above the 20-day high of $0.3947. Analysts highlighted the move’s potential for continuation but cautioned about risks of a false breakout and thin liquidity. The stock’s sharp intraday increase reflects optimism about the regulatory timeline, though confirmation in regular trading hours remains key to validate the trend.